



RECEIVED

MAR 26 2003

TECH CENTER 1600/2900

Docket No.: PF378P1D1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Moore et al

Application No.: 10/057,951

Group Art Unit: 1652

Filed: January 29, 2002

Examiner: E. Slobodyansky

For: Tissue Plasminogen Activator-Like Protease

#4
B.G.
3/27/03

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-BV listed on the attached Form PTO/SB/08.

Copies of references AA-BV were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 09/411,977, filed October 4, 1999 (now U.S. Patent No. 6,372,473), and to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the above-listed file for copies of references AA-BV. Accordingly, no copies of references AA-BV are enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference are not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants

Application No.: 10/057,951

Docket No.: PF378P1D1


do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Dated: March 19, 2003

Respectfully submitted,

By 
Mark J. Hyman
Registration No.: 46,789
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(240) 314-1224

MMW/MJH/KC/lcc